| Year |
Citation |
Score |
| 2022 |
Cyrta J, Prandi D, Arora A, Hovelson DH, Sboner A, Rodriguez A, Fedrizzi T, Beltran H, Robinson DR, Gopalan A, True L, Nelson PS, Robinson BD, Mosquera JM, Tomlins SA, ... Shen R, et al. Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies. The Journal of Pathology. PMID 35220606 DOI: 10.1002/path.5887 |
0.306 |
|
| 2017 |
Mo Q, Shen R, Guo C, Vannucci M, Chan KS, Hilsenbeck SG. A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data. Biostatistics (Oxford, England). PMID 28541380 DOI: 10.1093/Biostatistics/Kxx017 |
0.328 |
|
| 2015 |
Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, ... ... Shen R, et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. The New England Journal of Medicine. 372: 2481-98. PMID 26061751 DOI: 10.1056/Nejmoa1402121 |
0.509 |
|
| 2013 |
Shen R, Wang S, Mo Q. SPARSE INTEGRATIVE CLUSTERING OF MULTIPLE OMICS DATA SETS. The Annals of Applied Statistics. 7: 269-294. PMID 24587839 DOI: 10.1214/12-Aoas578 |
0.316 |
|
| 2013 |
Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 497: 67-73. PMID 23636398 DOI: 10.1038/Nature12113 |
0.316 |
|
| 2013 |
Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Domínguez JM, Shen R, Tuttle RM, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. The New England Journal of Medicine. 368: 623-32. PMID 23406027 DOI: 10.1056/Nejmoa1209288 |
0.32 |
|
| 2011 |
Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, Creaney J, Lake RA, Zakowski MF, Reva B, Sander C, Delsite R, Powell S, Zhou Q, Shen R, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nature Genetics. 43: 668-72. PMID 21642991 DOI: 10.1038/Ng.855 |
0.313 |
|
| 2011 |
Fury MG, Haque S, Stambuk H, Shen R, Carlson D, Pfister D. A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer. Cancer. 117: 795-801. PMID 20922785 DOI: 10.1002/Cncr.25464 |
0.32 |
|
| 2008 |
Varambally S, Laxman B, Mehra R, Cao Q, Dhanasekaran SM, Tomlins SA, Granger J, Vellaichamy A, Sreekumar A, Yu J, Gu W, Shen R, Ghosh D, Wright LM, Kladney RD, et al. Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. Neoplasia (New York, N.Y.). 10: 1285-94. PMID 18953438 DOI: 10.1593/Neo.08922 |
0.383 |
|
| 2007 |
Yu J, Cao Q, Mehra R, Laxman B, Yu J, Tomlins SA, Creighton CJ, Dhanasekaran SM, Shen R, Chen G, Morris DS, Marquez VE, Shah RB, Ghosh D, Varambally S, et al. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell. 12: 419-31. PMID 17996646 DOI: 10.1016/J.Ccr.2007.10.016 |
0.383 |
|
| 2007 |
Mehra R, Han B, Tomlins SA, Wang L, Menon A, Wasco MJ, Shen R, Montie JE, Chinnaiyan AM, Shah RB. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Research. 67: 7991-5. PMID 17804708 DOI: 10.1158/0008-5472.Can-07-2043 |
0.398 |
|
| 2007 |
Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM, Shah RB. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 20: 538-44. PMID 17334343 DOI: 10.1038/Modpathol.3800769 |
0.371 |
|
| 2006 |
Fu Z, Kitagawa Y, Shen R, Shah R, Mehra R, Rhodes D, Keller PJ, Mizokami A, Dunn R, Chinnaiyan AM, Yao Z, Keller ET. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. The Prostate. 66: 248-56. PMID 16175585 DOI: 10.1002/Pros.20319 |
0.371 |
|
| 2006 |
Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R, Montie JE, Pienta KJ, Sanda MG, Kantoff PW, Rubin MA, Wei JT, Ghosh D, Chinnaiyan AM. Autoantibody Signatures in Prostate Cancer The Journal of Urology. 175: 1706-1706. DOI: 10.1016/S0022-5347(06)00094-2 |
0.342 |
|
| 2005 |
Kim R, Demichelis F, Tang J, Riva A, Shen R, Gibbs DF, Mahavishno V, Chinnaiyan AM, Rubin MA. Internet-based Profiler system as integrative framework to support translational research. Bmc Bioinformatics. 6: 304. PMID 16364175 DOI: 10.1186/1471-2105-6-304 |
0.32 |
|
| 2005 |
Mehra R, Varambally S, Ding L, Shen R, Sabel MS, Ghosh D, Chinnaiyan AM, Kleer CG. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Research. 65: 11259-64. PMID 16357129 DOI: 10.1158/0008-5472.Can-05-2495 |
0.386 |
|
| 2005 |
Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R, Montie JE, Pienta KJ, Sanda MG, Kantoff PW, Rubin MA, Wei JT, Ghosh D, Chinnaiyan AM. Autoantibody signatures in prostate cancer. The New England Journal of Medicine. 353: 1224-35. PMID 16177248 DOI: 10.1056/Nejmoa051931 |
0.35 |
|
| 2005 |
Witkiewicz AK, Varambally S, Shen R, Mehra R, Sabel MS, Ghosh D, Chinnaiyan AM, Rubin MA, Kleer CG. Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 14: 1418-23. PMID 15941950 DOI: 10.1158/1055-9965.Epi-04-0607 |
0.35 |
|
| 2004 |
Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Research. 64: 9209-16. PMID 15604294 DOI: 10.1158/0008-5472.Can-04-2442 |
0.395 |
|
| 2004 |
Shen R, Ghosh D, Chinnaiyan AM. Prognostic meta-signature of breast cancer developed by two-stage mixture modeling of microarray data. Bmc Genomics. 5: 94. PMID 15598354 DOI: 10.1186/1471-2164-5-94 |
0.33 |
|
| 2004 |
Hofer MD, Fecko A, Shen R, Setlur SR, Pienta KG, Tomlins SA, Chinnaiyan AM, Rubin MA. Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. Neoplasia (New York, N.Y.). 6: 503-12. PMID 15548358 DOI: 10.1593/Neo.04157 |
0.347 |
|
| 2004 |
Shah RB, Kunju LP, Shen R, LeBlanc M, Zhou M, Rubin MA. Usefulness of basal cell cocktail (34betaE12 + p63) in the diagnosis of atypical prostate glandular proliferations. American Journal of Clinical Pathology. 122: 517-23. PMID 15487448 DOI: 10.1309/Wrm5-1C70-P1Nb-Fe4K |
0.341 |
|
| 2003 |
Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proceedings of the National Academy of Sciences of the United States of America. 100: 11606-11. PMID 14500907 DOI: 10.1073/Pnas.1933744100 |
0.32 |
|
| 2003 |
Zhou M, Shah R, Shen R, Rubin MA. Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells. The American Journal of Surgical Pathology. 27: 365-71. PMID 12604893 DOI: 10.1097/00000478-200303000-00010 |
0.351 |
|
| 2002 |
Dash A, Maine IP, Varambally S, Shen R, Chinnaiyan AM, Rubin MA. Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens. The American Journal of Pathology. 161: 1743-8. PMID 12414521 DOI: 10.1016/S0002-9440(10)64451-3 |
0.338 |
|
| Show low-probability matches. |